- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02961465
Effectiveness and Safety of Sacral Neuromodulation in Patients With Idiopathic Slow-transit Constipation
Effectiveness and Safety of Sacral Neuromodulation in Patients With Idiopathic Slow-transit Constipation Refractory to Conservative Treatments
Rationale: Previous reviews showed that the evidence regarding the effectiveness of sacral neuromodulation (SNM) in patients with therapy-resistant, idiopathic (slow-transit) constipation is of suboptimal quality. Furthermore, there is no estimate of costs and cost-effectiveness in this patient group.
Study design: A prospective cohort study with one group. This study is conducted next to a randomized controlled clinical trial (RCT) on 'the effectiveness and cost-effectiveness of sacral neuromodulation in patients with idiopathic slow-transit constipation refractory to conservative treatments' (for more information ClinicalTrial.gov ID: NCT02961582). This RCT is part of a temporary reimbursement arrangement, called conditional reimbursement of health care (in Dutch: Voorwaardelijke Toelating) of the National Health Care Institute (Zorginstituut Nederland). As part of this arrangement, the Ministry of Health, Welfare and Sports requires that SNM remains available for eligible patients during the conditional reimbursement period, also when inclusion of the RCT has ended. Furthermore, the Ministry requires that patients who received personalized conservative treatment in the RCT (control group), are offered SNM after completion of their follow-up of 6 months. As a result, the National Health Care Institute requires that the patients who receive SNM outside the RCT are included in a prospective cohort study to be able to collect data on them.
Aim: The aim of this prospective cohort study is to collect more (but uncontrolled) information regarding the safety and effectiveness of SNM.
Study population: Adolescent (14-17 years) and adult (18-80 years) patients with idiopathic slow-transit constipation refractory to conservative treatment.
Intervention: The intervention is SNM, a minimally invasive surgical procedure consisting of two phases. In the screening phase an electrode is inserted near the third sacral nerve and connected to an external stimulator. If the screening phase is successful (average defecation frequency (DF) ≥3 a week), the electrode is connected to a pacemaker that is implanted in the buttocks of the patient. If not successful, the pacemaker will be removed and patients receive conservative treatment.
Main study parameters/endpoints: The primary outcome is treatment success at 6 months, defined as an average DF of ≥3 a week according to a 3-week defecation diary and safety. Secondary outcomes are straining, sense of incomplete evacuation, constipation severity and generic (health-related) quality of life ((HR)QOL).
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Limburg
-
Maastricht, Limburg, Netherlands, 6229HX
- Maastricht University Medical Centre
-
-
Zuid-Holland
-
Gouda, Zuid-Holland, Netherlands, 2800 BB
- Groene Hart Ziekenhuis
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
The study population consists of adolescents (14-17 years) and adults (18-80 years) with idiopathic slow-transit constipation refractory to conservative treatment. As data regarding this population is limited it is virtually impossible to provide precise numbers of this patient population. However, some numbers are known:
- Average prevalences of idiopathic constipation of 16% and 19.2% are reported in Europe
- Of all patients treated for constipation, 5.6% is treated at the hospital
- It is estimated that 1% of the constipation patients who are treated with conservative treatment in hospitals, are unresponsive and are eligible for sacral neuromodulation
- Over the last 6 years, annually, on average, 25 patients were treated with SNM at the Maastricht UMC+ and the Groene Hart Ziekenhuis Gouda
Description
Inclusion Criteria:
- An average defecation frequency (DF) of <3 per week based on a 3-week defecation diary (patient-reported)
- Meet at least one other criterion of the Rome-IV criteria for idiopathic constipation based on the 3-week defecation diary (1)
- Refractory to conservative treatment
- Age: 14-80 years
Slow-transit constipation
(1) Rome-IV criteria for idiopathic constipation:
- Straining during ≥25% of defecations
- Lumpy or hard stools in ≥25% of defecations
- Sensation of incomplete evacuation for ≥25% of defecations
- Sensation of anorectal obstruction/blockage for ≥25% of defecations
- Manual manoeuvres to facilitate ≥25% of defecations
Exclusion Criteria:
- Obstructed outlet syndrome (objectified by defeacography)
- Irritable bowel syndrome (Rome-IV criteria for irritable bowel syndrome)
- Congenital or organic bowel pathology
- Rectal prolapse
- Anatomical limitations preventing placement of an electrode
- Skin and perineal disease with risk of infection
- Previous large bowel/rectal surgery
- Stoma
- Coexisting neurological disease
- Significant psychological co-morbidity as assessed subjectively by the investigator
- Being or attempting to become pregnant during study follow-up
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Sacral Neuromodulation (SNM)
|
SNM starts with a screening phase. In this phase a tined lead is inserted into the third sacral foramen and attached to an external stimulator, after which the patient enters a four-week stimulation test period. If the screening phase is successful (defecation frequency (DF) ≥3 a week), the external stimulator is changed for a pacemaker that is implanted in the buttocks. If the screening phase is unsuccessful (DF <3 a week), the lead is explanted. Patients are asked to limit the use of additional conservative treatments for constipation (such as laxatives and colonic irrigation) to what is necessary to relieve (the most severe) complaints. What is necessary to relieve complaints is determined by the patient.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment success at 6 months
Time Frame: 6 months
|
Treatment success is defined as an average defecation frequency of ≥ 3 a week based on a patient-reported defecation diary over a period of 3 weeks
|
6 months
|
Complications/adverse events
Time Frame: 6 months
|
Reported by the clinician in a case report form (CRF)
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients with a 50% reduction in the proportion of defecations with straining
Time Frame: Baseline, 1, 3 and 6 months, (12 months)
|
The proportion of defecations with straining is derived from the data in the 3 week defecation diary.
The reported proportion of defecations with straining is compared with the proportion of defecations with straining at baseline.
Patients are divided in two groups: 1) ≥50% reduction in the proportion of defecations with straining and 2) <50% reduction in the proportion of defecations with straining.
In patients who still have the pacemaker at 6 months, outcomes are als measured 12 months after inclusion to monitor the longer term effectiveness and safety of SNM.
|
Baseline, 1, 3 and 6 months, (12 months)
|
Proportion of patients with a 50% reduction in the proportion of defecations with a sense of incomplete evacuation
Time Frame: Baseline, 1, 3 and 6 months, (12 months)
|
The proportion of defecations with a sense of incomplete evacuation is derived from the data in the 3 week defecation diary.
The reported proportion of defecations with a sense of incomplete evacuation is compared with the proportion of defecations with a sense of incomplete evacuation at baseline.
Patients are divided in two groups: 1) ≥50% reduction in the proportion of defecations with a sense of incomplete evacuation and 2) <50% reduction in the proportion of defecations with a sense of incomplete evacuation.
In patients who still have the pacemaker at 6 months, outcomes are als measured 12 months after inclusion to monitor the longer term effectiveness and safety of SNM.
|
Baseline, 1, 3 and 6 months, (12 months)
|
Constipation severity
Time Frame: Baseline, 1, 3 and 6 months, (12 months)
|
Displayed with the score from the Wexner constipation score (WCS).
In patients who still have the pacemaker at 6 months, outcomes are als measured 12 months after inclusion to monitor the longer term effectiveness and safety of SNM.
|
Baseline, 1, 3 and 6 months, (12 months)
|
Generic (HR)QOL
Time Frame: Baseline, 1, 3 and 6 months, (12 months)
|
Displayed with the score from the EQ-5D-5L.
In patients who still have the pacemaker at 6 months, outcomes are als measured 12 months after inclusion to monitor the longer term effectiveness and safety of SNM.
|
Baseline, 1, 3 and 6 months, (12 months)
|
Collaborators and Investigators
Investigators
- Principal Investigator: Stéphanie O Breukink, Dr., Maastricht University Medical Centre
- Principal Investigator: Carmen D Dirksen, Prof. dr., Maastricht University Medical Centre
Publications and helpful links
General Publications
- Suares NC, Ford AC. Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis. Am J Gastroenterol. 2011 Sep;106(9):1582-91; quiz 1581, 1592. doi: 10.1038/ajg.2011.164. Epub 2011 May 24.
- Mugie SM, Benninga MA, Di Lorenzo C. Epidemiology of constipation in children and adults: a systematic review. Best Pract Res Clin Gastroenterol. 2011 Feb;25(1):3-18. doi: 10.1016/j.bpg.2010.12.010.
- van Wunnik BP, Peeters B, Govaert B, Nieman FH, Benninga MA, Baeten CG. Sacral neuromodulation therapy: a promising treatment for adolescents with refractory functional constipation. Dis Colon Rectum. 2012 Mar;55(3):278-85. doi: 10.1097/DCR.0b013e3182405c61.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- METC161044
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Constipation
-
usMIMA S.L.CompletedConstipation | Constipation Chronic Idiopathic | Constipation; NeurogenicSpain, United Kingdom
-
AbbVieIronwood Pharmaceuticals, Inc.RecruitingFunctional Constipation (FC) | Chronic Idiopathic Constipation (CIC)United States, United Kingdom, Bulgaria, Netherlands
-
usMIMA S.L.University of York; County Durham and Darlington NHS Foundation TrustNot yet recruitingConstipation | Constipation-predominant Irritable Bowel Syndrome | Constipation - Functional | Constipation Chronic Idiopathic | Constipation; Neurogenic
-
Institute of Medical Sciences and SUM HospitalNot yet recruitingFunctional Constipation | Constipation - Functional | Constipation Chronic Idiopathic | Fecal Impaction | Pediatric Functional ConstipationIndia
-
SK Life Science, Inc.CompletedChronic Constipation | Functional ConstipationUnited States
-
Cairo UniversityUnknownChronic Idiopathic Constipation | Functional ConstipationEgypt
-
ProgenaBiomeRecruitingConstipation | Constipation - Functional | Constipation Chronic Idiopathic | Constipation (Excl Faecal Impaction)United States
-
Chulalongkorn UniversityNot yet recruitingFunctional ConstipationThailand
-
Min-Tze LIONGDeyang People's HospitalRecruiting
-
AbbVieIronwood Pharmaceuticals, Inc.RecruitingFunctional ConstipationUnited States, Bulgaria, United Kingdom, Croatia, Germany, Hungary
Clinical Trials on Sacral Neuromodulation
-
Friedrich-Alexander-Universität Erlangen-NürnbergRecruitingAnorectal Malformations | Chronic Constipation With Overflow | Encopresis With Constipation and Overflow Incontinence | Hirschsprung's Disease | Sacral DysgenesisGermany
-
MedtronicNeuroRecruitingOveractive Bladder | Urinary Retention | Fecal IncontinenceUnited States
-
Seinajoki Central HospitalTurku University Hospital; Helsinki University Central Hospital; Oulu University... and other collaboratorsRecruiting
-
Cigli Regional Training HospitalCompleted
-
Hospital Universitari Vall d'Hebron Research InstituteInstitut d'Investigació Biomèdica de Girona Dr. Josep Trueta; Hospital Universitari...CompletedLow Anterior Resection Syndrome | Rectal Cancer | Sacral Neuromodulation - Interstim TherapySpain
-
University Hospital, GhentMedtronicCompletedUrinary Retention | Fecal Incontinence | Overactive Bladder Syndrome | Dysfunctional Voiding | Fowler SyndromeBelgium
-
Northwestern UniversityUniversity of Missouri-Columbia; University of Pennsylvania; University of Washington and other collaboratorsCompleted
-
University Hospital Inselspital, BerneCompleted
-
TriHealth Inc.TerminatedUrinary Urge IncontinenceUnited States
-
Medical University of ViennaRecruitingFaecal IncontinenceAustria